GSK to Highlight Results from the P-III (EAGLE-1) Study of Gepotidacin for Treating Uncomplicated Urogenital Gonorrhoea (GC) at ESCMID 2024
Shots:
- The P-III (EAGLE-1) study assessed the safety & efficacy of gepotidacin (2 doses of 3,000mg, oral) vs ceftriaxone (500mg, IM) + azithromycin (1,000mg) to treat uncomplicated urogenital gonorrhoea patients (n=~600). 1EP was microbiological response at the ToC visit 3-7 days post treatment
- The study demonstrated drug’s non-inferiority with a success rate of 92.6% vs 91.2% for the combination of ceftriaxone & azithromycin
- Moreover, the company concluded EAGLE-2 & EAGLE-3 studies assessing the safety & efficacy of gepotidacin (1,500mg, oral, BID for 5 days) vs nitrofurantoin (100mg, oral, BID for 5 days) to treat uncomplicated urinary tract infections (uUTI). The data was featured at ECCMID 2023 & published in The Lancet
Ref: GSK | Image: GSK
Related News:- GSK Reports Results from the P-III (EAGLE-1) Study of Gepotidacin for the Treatment of Urogenital Gonorrhoea (GC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
